OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
NEWTON, Mass., April 27, 2017 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2017 financial results and provide a company update on Thursday, May 4, 2017. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, May 4, 2017 to discuss the financial results and recent business developments.
To access the conference call, please dial (855) 437-4406 (local) or (484) 756-4292 (international) at least five minutes prior to the start time and refer to conference ID 10603764. A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, investors.karyopharm.com/events.cfm. An archived webcast will be available on the Company's website approximately two hours after the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). The Company's initial focus is on seeking regulatory approval and commercialization of its lead drug candidate, oral selinexor (KPT-330). To date, over 1,900 patients have been treated with selinexor and it is currently being evaluated in several mid- and later-phase clinical trials across multiple cancer indications, including multiple myeloma in combination with low-dose dexamethasone (STORM) and backbone therapies (STOMP), diffuse large B-cell lymphoma (SADAL), and liposarcoma (SEAL), among others. Karyopharm plans to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade®) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma in early 2017. In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has five investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.
Contacts: Michelle Carroll (212) 600-1902 [email protected]
